SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Mar, 21, 2023
$CDTX FDA decision will be made tomorrow $SAVA, $M... See more
Jan, 11, 2023
$SAVA I'm loving the move, can't wait for ... See more
JSPR
Jasper Therapeutics Inc
3.78%
$1.85 - $1.92
Feb 8th 2023 - Mar 22nd 2023
Jan, 30, 2023
Their therapies really work and it will be an easy... See more
Jan, 13, 2023
$JSPR FDA approval here a few weeks ago, this baby isn’t going down,
NNOX
Nano X Imaging Ltd
-27.77%
$9.11 - $6.58
Feb 7th 2023 - Mar 21st 2023
Mar, 4, 2023
$NNOX I believe they will get FDA approval soon a... See more
Feb, 13, 2023
What a nice surprise that would be if they can ann... See more
Mar, 21, 2023
$CDTX FDA decision will be made tomorrow $SAVA, $MDGL & $RETA boys I can easily see this up 200%-300% in my opinion on an approval.
Jan, 11, 2023
$SAVA I'm loving the move, can't wait for the approval, buy out at $500, sell at $1200.
Jan, 7, 2023
$SAVA diseases like Alzheimer’s will have more Than 1 drug approved for the indication.. being first is great,
Jan, 6, 2023
$SAVA FDA approved Biogen's AD drug is bullish for SAVA.
Jan, 6, 2023
$SAVA biib up 3.00 on approval sava will go up 100+ on approval
Jan, 6, 2023
no more speculation, now it's real, two FDA approved meds, two major products, top of the line in comparison of their rivals, for cheaper price, AND WITH NO MUCH COMPETITION!
Jan, 6, 2023
$SAVA When FDA approved Aduhelm (aducanumab), which was a failure, on June 7 2021, SAVA was up 33% within a day following that news! !
Nov, 6, 2022
This formula has already proved to be effective, and if FDA approved can potentially be sold for billions.
Oct, 20, 2022
This share price is a steal with those great Levo results this morning, and their other 3 approved and growing products.
Oct, 14, 2022
Simufilam boosts soluble level of Amyloid bera42 which in turn improves or maintains cognition in Alz patients This, along with its superior safety profile, will win the approval undoubtedly!
Jan, 30, 2023
Their therapies really work and it will be an easy approval with no sae.
Jan, 13, 2023
$JSPR FDA approval here a few weeks ago, this baby isn’t going down,
Jan, 4, 2023
positive PURSUIT outcome and FDA approval would open a multibillion-dollar commercial opportunity for Viveve.
Jan, 3, 2023
Buyout approval announced and still major upside.